In short
A3907 is an investigational drug being studied for the treatment of Primary Sclerosing Cholangitis (PSC), a chronic liver disease. This article discusses an open-label, Phase 2 clinical trial designed to assess the safety, tolerability, and effects of A3907 in adults with PSC. The study aims to evaluate different dosages of A3907 and its impact on bile acid levels, liver enzymes, and other relevant biomarkers in patients with PSC.
At a glance
- Study Type
- Open-label, Phase 2 clinical trial
- Drug
- A3907 (oral ASBT inhibitor)
- Condition
- Primary Sclerosing Cholangitis (PSC)
- Primary Objective
- Evaluate safety and tolerability of A3907
- Secondary Objectives
- Assess pharmacokinetics, effects on bile acid levels, liver enzymes, and biomarkers
- Dosages
- 10 mg and 30 mg once daily; 30 mg twice daily
- Treatment Duration
- 12 weeks
- Key Inclusion Criteria
- Adults 18-75, PSC diagnosis, elevated ALP, serum bile acid level > ULN
- Key Exclusion Criteria
- Secondary sclerosing cholangitis, recent biliary intervention, liver cirrhosis
What is A3907?
A3907 is a new medication being developed to treat Primary Sclerosing Cholangitis (PSC), a chronic liver disease. It is currently undergoing clinical trials to evaluate its safety and effectiveness. A3907 is taken orally as a film-coated tablet, making it convenient for patients to use.
Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a chronic liver disease that affects the bile ducts. Bile ducts are tubes that carry bile (a digestive fluid) from the liver to the small intestine. In PSC, inflammation causes scarring and narrowing of these ducts, which can lead to liver damage over time.
How A3907 Works
A3907 is a type of medication called an ASBT inhibitor. ASBT stands for Apical Sodium Bile Acid Transporter. This medication works by: Inhibiting (blocking) the ASBT, which is responsible for transporting bile acids Lowering bile acid levels in the body Modulating (changing) bile acid transport within the bile ducts By doing this, A3907 might help reduce liver cell damage in diseases like PSC where there's a problem with bile flow (cholestatic liver diseases).
Ongoing Clinical Trial
A3907 is currently being studied in a Phase 2 clinical trial. This trial is: Open-label, meaning both the researchers and participants know which treatment is being given Designed to evaluate the safety, tolerability, and effects of A3907 in adults with PSC Testing two dose levels: 10 mg and 30 mg, taken orally once daily for 12 weeks Also including a group of patients taking 30 mg twice daily Including a group of PSC patients with a Clinically Relevant Stricture (CRS), which is a severe narrowing of the bile ducts The study will last for 12 weeks, with follow-up visits to monitor the participants' health.
Potential Benefits of A3907
While the full benefits of A3907 are still being studied, researchers hope it may: Improve liver health in PSC patients Reduce levels of liver enzymes, which can be a sign of liver damage Lower bile acid levels in the body Potentially slow down the progression of PSC However, it's important to note that these potential benefits are still being investigated in the clinical trial.
Eligibility Criteria for the Study
To participate in the A3907 clinical trial, patients must meet certain criteria. Some key eligibility factors include: Being between 18 and 75 years old Having a confirmed diagnosis of PSC for at least 6 months Having elevated levels of certain liver enzymes Not having certain other liver conditions or severe liver damage Not being pregnant or breastfeeding There are additional specific criteria that healthcare providers will use to determine if a patient is eligible for the study.
Safety and Side Effects
The primary goal of this clinical trial is to evaluate the safety and tolerability of A3907. This means researchers will be closely monitoring: Any side effects that occur during the study How well patients tolerate the medication Any changes in liver function or other health markers As with any new medication, there may be unknown risks or side effects. Participants in the study will be closely monitored by healthcare professionals throughout the trial.
It's important to remember that A3907 is still an experimental medication. While it shows promise, more research is needed to fully understand its effects and determine if it will become an approved treatment for PSC in the future.